Our findings are consistent with the notion that CH with TET2 mutations is different from CH with DNMT3A or ASXL1 mutations as indicated by some clinical studies, for example, CH with TET2 mutations has been linked to chronic obstructive pulmonary diseases (52) but not CH with DNMT3A mutations. This evidence concerns the gene TET2 and cyclic hematopoiesis.